Skip to content

Happy Baby Hearts Study

Renal NIRS Monitoring to Detect Coarctation of the Aorta - A Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05842876
Enrollment
82
Registered
2023-05-06
Start date
2023-04-19
Completion date
2025-01-21
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coarctation of Aorta

Brief summary

The goal of this observational study is to determine the feasibility of renal Near Infrared Spectroscopy (NIRS) monitoring in the newborn nursery for newborns at low risk of coarctation of the aorta (CoA). The main questions it aims to answer are: * whether continuous renal NIRS monitoring is feasible; * whether NIRS monitoring results in higher nursing and parent/caregiver satisfaction than current standard monitoring; and, * whether participants who develop CoA will spend a smaller proportion of time within the normal range than patients who do not have CoA. Participants will be observed through continuous renal oxygenation monitoring with NIRS.

Interventions

Survey to assess which method of monitoring is preferred

DEVICEContinuous Renal NIRS Monitoring

Renal oxygenation data collected every 6 seconds

DIAGNOSTIC_TESTStandard Clinical Care

q6 h BP, q6 h Pulse ox, Echo at 24-72h

Sponsors

Meriter Foundation
CollaboratorOTHER
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Neonate Inclusion Criteria: * Delivered at ≥ 35 weeks of gestation * \<12 hours of age * Inpatient at Meriter Hospital, Inc. NICU or Newborn Nursery or AFCH PICU or NICU * Diagnosed as at risk for CoA Neonate

Exclusion criteria

* Major congenital anomalies of the kidney * Attending physician's discretion to not place sensors due to clinical concerns * In the researcher's medical opinion, there is a significant likelihood that the neonate would not survive the first 3 days of life Primary Caregiver Inclusion Criteria: * Able to understand and the willing to sign a written informed consent document * Willing to comply with all study procedures and be available for the duration of the study * Birth parent (i.e., the parent who gave birth to the baby) who is the primary caregiver of a neonate who is eligible to participate in study * Agrees to enroll neonate into study * Aged 15 years or older * Pregnant mother with a baby diagnosed prenatally as at risk for CoA will be eligible for the study. They must also meet the following criteria: * Require an arch watch care plan as a results of prenatal ultrasonography findings * Agree to enroll offspring into the study at birth Primary Caregiver

Design outcomes

Primary

MeasureTime frameDescription
Percent of time monitoredUp to 2 weeks post-delivery, on averageAmount of time continuously monitored will be calculated
Count of adverse and unexpected eventsUp to 2 weeks post-deliveryAll adverse and unexpected events will be recorded

Secondary

MeasureTime frameDescription
Change in nursing satisfaction with renal NIRS monitoringStudy start to one year laterA subjective description of survey responses in addition to determining which method of monitoring is preferred: NIRS vs. Enhanced BP/Pulse ox checks. Survey will be conducted at the beginning of the study, and one year later.
Parent/caregiver satisfaction with renal NIRS monitoringUp to 2 weeks post-delivery, on averageA subjective description of survey responses in addition to determining which method of monitoring is preferred: NIRS vs. Enhanced BP/Pulse ox checks
Renal oxygen trendsThrough study completion, approximately 1 yearA permutation test will be used to compare the distribution of proportions (of time spent within normal range) between the two groups (CoA vs. normal)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026